Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

CXCR2: A Novel Mediator of Mammary Tumor Bone Metastasis.

Sharma B, Nannuru KC, Saxena S, Varney ML, Singh RK.

Int J Mol Sci. 2019 Mar 12;20(5). pii: E1237. doi: 10.3390/ijms20051237.

2.

ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.

Hatsell SJ, Idone V, Wolken DM, Huang L, Kim HJ, Wang L, Wen X, Nannuru KC, Jimenez J, Xie L, Das N, Makhoul G, Chernomorsky R, D'Ambrosio D, Corpina RA, Schoenherr CJ, Feeley K, Yu PB, Yancopoulos GD, Murphy AJ, Economides AN.

Sci Transl Med. 2015 Sep 2;7(303):303ra137. doi: 10.1126/scitranslmed.aac4358.

3.

Host Cxcr2-dependent regulation of mammary tumor growth and metastasis.

Sharma B, Nannuru KC, Varney ML, Singh RK.

Clin Exp Metastasis. 2015 Jan;32(1):65-72. doi: 10.1007/s10585-014-9691-0. Epub 2014 Dec 16.

4.

Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis.

Sharma B, Nawandar DM, Nannuru KC, Varney ML, Singh RK.

Mol Cancer Ther. 2013 May;12(5):799-808. doi: 10.1158/1535-7163.MCT-12-0529. Epub 2013 Mar 6.

5.

Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis.

Nannuru KC, Sharma B, Varney ML, Singh RK.

J Carcinog. 2011;10:40. doi: 10.4103/1477-3163.92308. Epub 2011 Dec 31.

6.

Tumor-stromal interactions in bone metastasis.

Nannuru KC, Singh RK.

Curr Osteoporos Rep. 2010 Jun;8(2):105-13. doi: 10.1007/s11914-010-0011-6. Review.

PMID:
20425618
7.

Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.

Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK.

Cancer Res. 2010 May 1;70(9):3494-504. doi: 10.1158/0008-5472.CAN-09-3251. Epub 2010 Apr 20.

8.

Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-beta signaling and bone destruction.

Wilson TJ, Nannuru KC, Singh RK.

Mol Cancer Res. 2009 Aug;7(8):1224-33. doi: 10.1158/1541-7786.MCR-09-0028. Epub 2009 Aug 11.

9.

Cathepsin G-mediated enhanced TGF-beta signaling promotes angiogenesis via upregulation of VEGF and MCP-1.

Wilson TJ, Nannuru KC, Futakuchi M, Singh RK.

Cancer Lett. 2010 Feb 28;288(2):162-9. doi: 10.1016/j.canlet.2009.06.035. Epub 2009 Jul 30.

10.

Enhanced expression and shedding of receptor activator of NF-kappaB ligand during tumor-bone interaction potentiates mammary tumor-induced osteolysis.

Nannuru KC, Futakuchi M, Sadanandam A, Wilson TJ, Varney ML, Myers KJ, Li X, Marcusson EG, Singh RK.

Clin Exp Metastasis. 2009;26(7):797-808. doi: 10.1007/s10585-009-9279-2. Epub 2009 Jul 10.

PMID:
19590968
11.

Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion.

Singh S, Sadanandam A, Varney ML, Nannuru KC, Singh RK.

Int J Cancer. 2010 Jan 15;126(2):328-36. doi: 10.1002/ijc.24714.

12.

CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion.

Singh S, Nannuru KC, Sadanandam A, Varney ML, Singh RK.

Br J Cancer. 2009 May 19;100(10):1638-46. doi: 10.1038/sj.bjc.6605055. Epub 2009 Apr 28.

13.

Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.

Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R, Singh RK.

Clin Cancer Res. 2009 Apr 1;15(7):2380-6. doi: 10.1158/1078-0432.CCR-08-2387. Epub 2009 Mar 17.

14.

Cathepsin G recruits osteoclast precursors via proteolytic activation of protease-activated receptor-1.

Wilson TJ, Nannuru KC, Singh RK.

Cancer Res. 2009 Apr 1;69(7):3188-95. doi: 10.1158/0008-5472.CAN-08-1956. Epub 2009 Mar 17.

15.

Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.

Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, Shirai T, Sato SY, Singh RK.

Cancer Sci. 2009 Jan;100(1):71-81. doi: 10.1111/j.1349-7006.2008.01012.x. Epub 2008 Nov 25.

16.

Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.

Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK.

Cancer Res. 2008 Jul 15;68(14):5803-11. doi: 10.1158/0008-5472.CAN-07-5889.

Supplemental Content

Loading ...
Support Center